UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000046049
Receipt number R000052560
Scientific Title Efficacy and safety of Ferric carboxymaltose injection compared with oral iron for the treatment of postpartum anemia in Japan: a randomized controlled clinical trial
Date of disclosure of the study information 2021/12/01
Last modified on 2023/05/14 16:05:08

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Efficacy and safety of Ferric carboxymaltose injection compared with oral iron for the treatment of postpartum anemia in Japan: a randomized controlled clinical trial

Acronym

Efficacy and safety of Ferric carboxymaltose injection compared with oral iron for the treatment of postpartum anemia in Japan: a randomized controlled clinical trial

Scientific Title

Efficacy and safety of Ferric carboxymaltose injection compared with oral iron for the treatment of postpartum anemia in Japan: a randomized controlled clinical trial

Scientific Title:Acronym

Efficacy and safety of Ferric carboxymaltose injection compared with oral iron for the treatment of postpartum anemia in Japan: a randomized controlled clinical trial

Region

Japan


Condition

Condition

postpartum anemia

Classification by specialty

Obstetrics and Gynecology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

The purpose of this study is to investigate the efficacy and safety of Ferric carboxymaltose injection compared with oral iron for the treatment of postpartum anemia.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Change in Hb level after 2 weeks of treatment

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Active

Stratification

YES

Dynamic allocation


Institution consideration


Blocking

YES

Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Ferric carboxymaltose injection 500mg twice every two weeks.

Interventions/Control_2

Dried Ferrous Sulfate 210mg per day for 4 weeks

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Female

Key inclusion criteria

Patients with Hb less than 10g/dL and ferritin less than 500 ng/mL after vaginal delivery or cesarean section. Patients weighing 35 kg or more

Key exclusion criteria

1) Patients whose CRP level measured exceeds 20 mg/L
(2) Patients with hematological diseases
(3) Patients with serious hepatic disorder, renal disorder, or cardiovascular disease
4) Persons who have received a blood transfusion within 1 week
(5) Patients with malignant tumors
(6) Patients with a history of serious drug allergy such as anaphylactic shock or a history of serious adverse drug reactions.

Target sample size

60


Research contact person

Name of lead principal investigator

1st name Takeshi
Middle name
Last name Nagao

Organization

Jikei university school of medicine

Division name

Division of obstetrics and gynecology

Zip code

105-8471

Address

3-19-18, Nishishinbashi, Minatoku, Tokyo

TEL

03-3433-1111

Email

takeshi.n.900113@gmail.com


Public contact

Name of contact person

1st name Takeshi
Middle name
Last name Nagao

Organization

Jikei university school of medicine

Division name

Division of obstetrics and gynecology

Zip code

105-8471

Address

3-19-18, Nishishinbashi, Minatoku, Tokyo

TEL

03-3433-1111

Homepage URL


Email

takeshi.n.900113@gmail.com


Sponsor or person

Institute

Jikei university school of medicine

Institute

Department

Personal name



Funding Source

Organization

none

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Jikei university school of medicine Institutional Review Board

Address

3-19-18, Nishishinbashi, Minatoku, Tokyo

Tel

03-3433-1111

Email

takeshi.n.900113@gmail.com


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2021 Year 12 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2021 Year 11 Month 01 Day

Date of IRB

2021 Year 09 Month 24 Day

Anticipated trial start date

2021 Year 12 Month 01 Day

Last follow-up date

2023 Year 12 Month 01 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2021 Year 11 Month 11 Day

Last modified on

2023 Year 05 Month 14 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000052560


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name